Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
NYSE MKT:PLX
Protalix (PLX) Stock Price & Analysis
655 Followers
PLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.00 - $3.55
Previous Close$2.09
Volume995.70K
Average Volume (3M)2.13M
Market Cap
$135.74M
Enterprise Value$136.27M
Total Cash (Recent Filing)$33.04M
Total Debt (Recent Filing)$33.57M
Price to Earnings (P/E)-6.7
Beta0.84
Next Earnings
Aug 14, 2023EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding65,414,917
10 Day Avg. Volume2,133,552
30 Day Avg. Volume2,132,533
Standard Deviation0.21
R-Squared0.13
Alpha0.00196
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)14.26
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.19
Enterprise Value/Gross Profit4.86
Enterprise Value/Ebitda-14.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Protalix News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.00 and its highest was $3.55 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Currently, no data Available
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Aug 14, 2023 which is in 74 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on May 04, 2023. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.05.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Overvalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -$0.04.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 67,530,754 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Among the largest hedge funds holding Protalix Biotherapeutics’s share is Highbridge Capital Management LLC. It holds Protalix Biotherapeutics’s shares valued at N/A.
---
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PLX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Protalix Biotherapeutics
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. Protalix Biotherapeutics was founded on November 30, 1995 and is headquartered in Carmiel, Israel.
---
Top 5 ETFs holding PLX
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold PLX. The ETFs are listed according to market value of PLX within the ETF
---
---